Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033293 · ClinicalTrials.gov registry record · Phase 3
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT00033293 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 53 participants.
The verdict
NCT00033293, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements associated with neuroblastoma. Drugs used in chemotherapy, work in different ways to stop tumor cells from dividing so they stop growing or die. Steroid therapy decreases inflammation. Combining chemotherapy and steroid therapy with immunoglobulin may be effective in treating abnormal muscle movement associated with neuroblastoma.
Interventions
- DRUG Cyclophosphamide
- PROCEDURE Magnetic Resonance Imaging
- OTHER Laboratory Biomarker Analysis
- DRUG Prednisone
- OTHER Clinical Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2004-03-15 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033293
The ClinicalTrials.gov registry entry for NCT00033293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00033293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033293 about?
NCT00033293 is a clinical study titled "Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma". This randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements associated with neuroblastoma. Drugs used in chemotherapy, work in differ...
What is the current status of trial NCT00033293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2004-03-15. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT00033293?
The interventions under investigation include: Cyclophosphamide (DRUG), Magnetic Resonance Imaging (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Prednisone (DRUG), Clinical Observation (OTHER).
Who is sponsoring clinical trial NCT00033293?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.